Metrics to compare | ZSQR | Peers Peers - average of corresponding metrics from companies closely matching ZSQR: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZSQRPeersSector |
|---|---|---|---|---|
P/E Ratio | −7.8x | 0.0x | −0.5x | |
PEG Ratio | −0.16 | 0.00 | 0.00 | |
Price/Book | 6.9x | 0.0x | 2.6x | |
Price / LTM Sales | 68.6x | 0.0x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 47.1% | |
Fair Value Upside | Unlock | 0.0% | 6.2% | Unlock |
As of April 24, 2026, Coeptis Therapeutics Holdings, Inc. was acquired by Z Squared Inc., in a reverse merger transaction. Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.